Monoclonal Antibodies In Veterinary Health Market Size, Share | Report 2022-2030
The global monoclonal antibodies in veterinary health market was surpassed at USD 0.7 billion in 2021 and is expected to hit around USD 2.82 billion by 2030, growing at a CAGR of 16.75% from 2022 to 2030.
Increasing pet population coupled with the rising pet expenditure is expected to boost the market growth. Furthermore, the growing prevalence of canine atopic dermatitis is also likely to drive market growth over the forecast period.
Despite disruption due to the COVID-19 pandemic, the animal health industry witnessed a steady growth of 8% from 2019 to 2020. The economic downturn is relatively lower in the animal health market as compared to others. There will be a shift in business models for veterinarians. Traditional veterinary practices generate a majority of their revenues from selling high-margin products like pharmaceuticals.
The growing incidence of cancer, especially in dogs, is anticipated to provide a growth platform for the market. According to the American Veterinary Medical Association (AVMA), around 1 in 4 dogs are expected to suffer from neoplasia at some point in their lives. Neoplasia is a common type of cancer in dogs. Pain management is one of the most important aspects of the treatment of neoplasia in dogs. This can also be catered to using monoclonal antibody treatment.
The market is highly competitive and consists of several major players. With the emergence of immense opportunities in the market, various players in the market are making investments to emerge as leading players. For instance, in October 2021, Zoetis invested in new manufacturing and development facility in Ireland, to increase its Monoclonal Antibodies (mAbs) production capabilities. This is anticipated to enhance its veterinary therapeutic biopharmaceuticals portfolio. Moreover, in August 2021, Elanco acquired Kindred Biosciences for approximately USD 444 million. This supported the company’s access to the dermatology market, complemented its product pipeline, and enhanced R&D capabilities in biologics and monoclonal antibodies.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 0.7 billion |
| Revenue Forecast by 2030 | USD 2.82 billion |
| Growth rate from 2022 to 2030 | CAGR of 16.75% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Animal type, application, end-user, region |
| Companies Covered |
Zoetis; Merck & Co, Inc.; Elanco; Boehringer Ingelheim GmbH; Indian Immunologicals Ltd; Virbac |
Animal Type Insights
The dogs' segment held the highest share in 2021 owing to the availability of more monoclonal antibody products for dogs in the market. In addition to this, the population of dogs as pets is also rising, along with which expenditure on their health is also rising, which is further boosting the market growth. According to data published by the Pet Food Manufacturers’ Association, as of 2021, there were 12 million pet dogs in the U.K. This accounted for 33% of households.
The others segment is estimated to witness the fastest growth rate of 17.3% over the forecast period. Other animals include cats, horses, and livestock animals. The rising prevalence of various chronic diseases in animals along with the rising adoption of pet insurance is also anticipated to fuel the market growth. Furthermore, according to the American Society for the Prevention of Cruelty to Animals, in the U.S. around 85.8 million pets owned are cats, as compared to dogs (78 million). In terms of ownership, this amounts to 35% of households.
End-User Insights
By end-user, Veterinary Hospitals accounted for the largest share of the market in 2021. This is owing to the presence of novel therapies. Furthermore, the number of veterinary hospitals along with the number of veterinarians is rising, which leads to positive market growth. According to a report published by Petpedia.co, in 2018, there were 84,200 veterinarians in the U.S. This number was estimated to increase by around 14,200 by 2029.
The others segment is anticipated to grow at the highest CAGR of 17.6% during the projected period. Others’ segment includes clinics, research organizations, and academic institutes, among others. Increasing research activities for the development of novel monoclonal antibody therapeutic options is also anticipated to fuel market growth. Furthermore, growing awareness regarding advanced veterinary therapeutic alternatives is also estimated to boost the market growth.
Application Insights
The Dermatology segment is estimated to hold the largest market share of around 56% in 2021 owing to the presence of various products in this category. In addition to this, the growing incidences of atopic dermatitis in animals coupled with other infectious skin diseases are expected to boost the market growth. According to a report published by Scientific Reports in 2021, the prevalence of S. pseudintermedius in healthy and sick cats was 2.49% and 7.61%, respectively in Poland. S. pseudintermedius or Staphylococcus pseudintermedius is a type of bacterial infection in canines and felines.
The Others segment is anticipated to witness the fastest growth rate of 17.7% over the projected period. Others included diseases such as cancer, arthritis, and various infectious diseases, among others. The fastest growth is attributed to various R&D activities to develop innovative treatment options. Furthermore, the pain segment is also expected to account for a significant market share in 2021 owing to the presence of various products in the segment.
Regional Insights
North America is anticipated to dominate the global market with a share of around 44% in 2021. This is owing to the various initiatives undertaken by the government and private sector coupled with the growing adoption of pet insurance. Furthermore, the presence of key companies in the U.S. is also likely to boost the market growth. North American Pet Health Insurance Association, Inc. reported that the pet insurance industry is growing at a notable rate of 23.4% over the last few years. Moreover, at the end of 2020, about 3.45 million pets were insured across the North America region.
The market in the Asia Pacific is likely to grow at the highest CAGR of around 19.9% over the projected period owing to the rising emergence of local players along with the growing number of veterinary hospitals and clinics. Furthermore, the increasing adoption of pets along with the awareness regarding their diseases and the availability of treatment alternatives is further expected to boost the market growth.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Monoclonal Antibodies In Veterinary Health Market
5.1. COVID-19 Landscape: Monoclonal Antibodies In Veterinary Health Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Monoclonal Antibodies In Veterinary Health Market, By Application
8.1. Monoclonal Antibodies In Veterinary Health Market, by Application, 2022-2030
8.1.1 Dermatology
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Pain
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Monoclonal Antibodies In Veterinary Health Market, By Animal Type
9.1. Monoclonal Antibodies In Veterinary Health Market, by Animal Type, 2022-2030
9.1.1. Dogs
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Others
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Monoclonal Antibodies In Veterinary Health Market, By End-User
10.1. Monoclonal Antibodies In Veterinary Health Market, by End-User, 2022-2030
10.1.1. Veterinary Hospitals
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Others
10.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Monoclonal Antibodies In Veterinary Health Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Application (2017-2030)
11.1.2. Market Revenue and Forecast, by Animal Type (2017-2030)
11.1.3. Market Revenue and Forecast, by End-User (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Animal Type (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End-User (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Animal Type (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End-User (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.2. Market Revenue and Forecast, by Animal Type (2017-2030)
11.2.3. Market Revenue and Forecast, by End-User (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Animal Type (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End-User (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Animal Type (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End-User (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Animal Type (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End-User (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Animal Type (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End-User (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.2. Market Revenue and Forecast, by Animal Type (2017-2030)
11.3.3. Market Revenue and Forecast, by End-User (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Animal Type (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End-User (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Animal Type (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End-User (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Animal Type (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End-User (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Animal Type (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End-User (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.2. Market Revenue and Forecast, by Animal Type (2017-2030)
11.4.3. Market Revenue and Forecast, by End-User (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Animal Type (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End-User (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Animal Type (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End-User (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Animal Type (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End-User (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Animal Type (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End-User (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.5.2. Market Revenue and Forecast, by Animal Type (2017-2030)
11.5.3. Market Revenue and Forecast, by End-User (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Animal Type (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End-User (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Animal Type (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End-User (2017-2030)
Chapter 12. Company Profiles
12.1. Zoetis
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Merck & Co, Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Elanco
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Boehringer Ingelheim GmbH
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Indian Immunologicals Ltd
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Virbac
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers